专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2010130804A1 COMBINATORIAL ENGINEERING 审中-公开
标题翻译：组合工程
公开(公告)号：WO2010130804A1
公开(公告)日：2010-11-18
申请号：PCT/EP2010/056588
申请日：2010-05-12
申请人： BOEHRINGER INGELHEIM INTERNATIONAL GMBH , FLORIN, Lore , ENENKEL, Barbara , FUSSENEGGER, Martin , KAUFMANN, Hitto , SANTORO, Raffaella
发明人： FLORIN, Lore , ENENKEL, Barbara , FUSSENEGGER, Martin , KAUFMANN, Hitto , SANTORO, Raffaella
IPC分类号： C12N15/67 , C12N15/63 , C12N15/113 , C12P21/02
CPC分类号： C12N15/63 , C12N15/113 , C12N15/67 , C12N2310/14 , C12N2310/141 , C12P21/02
摘要： The invention concerns the field of cell culture technology. It concerns production host cell lines with increased expression of ribosomal RNA (rRNA) achieved through introduction of nucleic acids encoding UBF or reducing expression of NoRC proteins, especially of TIP-5. Those cell lines have improved secretion and growth characteristics in comparison to control cell lines. The invention further concerns a method of producing proteins using the cells generated by the described method.
摘要翻译：本发明涉及细胞培养技术领域。它涉及通过引入编码UBF的核酸或减少NoRC蛋白，特别是TIP-5的表达而实现的核糖体RNA（rRNA）表达增加的生产宿主细胞系。与对照细胞系相比，这些细胞系具有改善的分泌和生长特性。本发明还涉及使用由所述方法产生的细胞产生蛋白质的方法。

2. 发明申请

WO2010130800A1 IMPROVED CELL LINES HAVING REDUCED EXPRESSION OF NOCR AND USE THEREOF 审中-公开
标题翻译：改进的细胞系具有减少的NOCR表达和其使用
公开(公告)号：WO2010130800A1
公开(公告)日：2010-11-18
申请号：PCT/EP2010/056583
申请日：2010-05-12
申请人： BOEHRINGER INGELHEIM INTERNATIONAL GMBH , FLORIN, Lore , ENENKEL, Barbara , FUSSENEGGER, Martin , KAUFMANN, Hitto , SANTORO, Raffaella
发明人： FLORIN, Lore , ENENKEL, Barbara , FUSSENEGGER, Martin , KAUFMANN, Hitto , SANTORO, Raffaella
IPC分类号： C12N15/11
CPC分类号： C12N15/1136 , C12N15/111 , C12N15/113 , C12N15/85 , C12N2310/14 , C12P21/00
摘要： The invention concerns the field of cell culture technology. It concerns production host cell lines with increased expression of ribosomal RNA (rRNA) achieved through reducing expression of NoCR proteins, especially of TIP-5. Those cell lines have improved secretion and growth characteristics in comparison to control cell lines. The invention further concerns a method of producing proteins using the cells generated by the described method.
摘要翻译：本发明涉及细胞培养技术领域。它涉及通过减少NoCR蛋白表达，特别是TIP-5而实现的核糖体RNA（rRNA）表达增加的生产宿主细胞系。与对照细胞系相比，这些细胞系具有改善的分泌和生长特性。本发明还涉及使用由所述方法产生的细胞产生蛋白质的方法。

3. 发明申请

WO2009080299A1 SM-PROTEIN BASED SECRETION ENGINEERING 审中-公开
标题翻译：基于SM蛋白的分泌工程
公开(公告)号：WO2009080299A1
公开(公告)日：2009-07-02
申请号：PCT/EP2008/010882
申请日：2008-12-19
申请人： BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG , KAUFMANN, Hitto , BECKER, Eric , FLORIN, Lore , FUSSENEGGER, Martin , PENG, Ren-Wang , STUDTS, Joey, M.
发明人： KAUFMANN, Hitto , BECKER, Eric , FLORIN, Lore , FUSSENEGGER, Martin , PENG, Ren-Wang , STUDTS, Joey, M.
IPC分类号： C12P21/02 , C12N15/11 , C12N15/12 , C12N15/63 , A61K38/00 , A61K39/00 , A61K48/00 , C12N1/15 , C12N1/21 , C12N5/10
CPC分类号： C07K14/705 , C12N15/113 , C12N2310/11 , C12N2310/14 , C12P21/02
摘要： The present invention concerns the field of cell culture technology. It describes a novel method for enhancing the secretory transport of proteins in eukaryotic cells by heterologous expression of Munc18c, Sly1 or other members of the SM protein family. This method is particularly useful for the generation of optimized host cell systems with enhanced production capacity for the expression and manufacture of recombinant protein products.
摘要翻译：本发明涉及细胞培养技术领域。它描述了一种用于通过异源表达Munc18c，Sly1或SM蛋白家族的其他成员来增强真核细胞中蛋白质的分泌转运的新方法。该方法对于产生具有增强的生产能力的优化的宿主细胞系统特别有用，用于表达和制造重组蛋白质产物。

4. 发明申请

WO2003083093A1 HOST CELLS HAVING IMPROVED CELL SURVIVAL PROPERTIES AND METHODS TO GENERATE SUCH CELLS 审中-公开
标题翻译：具有改善细胞存活性质的宿主细胞和产生这种细胞的方法
公开(公告)号：WO2003083093A1
公开(公告)日：2003-10-09
申请号：PCT/EP2003/003063
申请日：2003-03-25
申请人： BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG , ENENKEL, Barbara , MEENTS, Heiko , FUSSENEGGER, Martin
发明人： ENENKEL, Barbara , MEENTS, Heiko , FUSSENEGGER, Martin
IPC分类号： C12N5/10
CPC分类号： C12N5/00 , C12N2500/90 , C12N2501/48 , C12N2510/02
摘要： The present invention relates to genetically engineered mammalian host cells comprising an enhanced level of active anti-apoptosis genes and methods to generate such host cells. More particularly, the invention pertains to methods which modulate the level of anti-apoptosis active genes within host cells and to host cells showing an enhanced cell viability by delaying/inhibiting programmed cell death naturally occurring in such cells. The present invention also provides new anti-apoptosis genes suitable fro the preparing host cells showing an enhanced cell viability by delaying/inhibiting programmed cell death naturally occurring in such cells.
摘要翻译：本发明涉及包含增强水平的活性抗凋亡基因的遗传工程哺乳动物宿主细胞和产生这种宿主细胞的方法。更具体地，本发明涉及通过延迟/抑制天然存在于这种细胞中的程序性细胞死亡来调节宿主细胞内抗凋亡活性基因水平和宿主细胞的方法，所述宿主细胞显示增强的细胞活力。本发明还提供适用于通过延迟/抑制在这种细胞中天然存在的程序性细胞死亡而显示增强的细胞活力的通过制备宿主细胞适合的新的抗凋亡基因。

5. 发明申请

WO2009080432A2 COMPOSITION FOR TREATMENT OF TUBERCULOSIS 审中-公开
标题翻译：用于治疗结肠癌的组合物
公开(公告)号：WO2009080432A2
公开(公告)日：2009-07-02
申请号：PCT/EP2008/066124
申请日：2008-11-25
申请人： ETH ZURICH , FUSSENEGGER, Martin , WEBER, Wilfried , SCHOENMAKERS, Ronald
发明人： FUSSENEGGER, Martin , WEBER, Wilfried , SCHOENMAKERS, Ronald
IPC分类号： A61K45/06 , A61K31/4409 , A61P31/06
CPC分类号： A61K31/17 , A61K31/4409 , A61K45/06 , A61K2300/00
摘要： The invention relates to a pharmaceutical composition comprising a compound preventing EthR from binding to the eth A promoter, for example a compound of formula (1) wherein R 1 is optionally substituted phenyl or optionally substituted pyridyl; R 2 is (CH 2 ) n wherein n is 1, 2, 3 or 4; R 3 is CH 3 (CH 2 ) m wherein m is 0, 1, 2 or 3; X 1 is O, S, NH, N(CH 3 ) or CH 2 ; and X 2 is O, S or NH; in particular 2-phenylethyl butyrate, and a thioamide or thiourea of formula (2) wherein R 4 is optionally substituted phenyl, optionally substituted pyridyl, optionally substituted indolyl, -NR 7 R 8 ; or -NH-N=CH-R 9 ; and substituents R 5 to R 9 have the meanings indicated in the description, in particular ethionamide. The pharmaceutical composition is useful, e.g., in the treatment of multidrug-resistant tuberculosis.
摘要翻译：本发明涉及包含防止EthR与ethA启动子结合的化合物的药物组合物，例如其中R 1为任选取代的苯基或任选取代的吡啶基的式（1）化合物; R2是（CH2）n，其中n是1,2,3或4; R3是CH3（CH2）m，其中m是0,1,2或3; X 1是O，S，NH，N（CH 3）或CH 2; X2是O，S或NH; 特别是丁酸2-苯基乙酯和式（2）的硫代酰胺或硫脲，其中R 4是任选取代的苯基，任选取代的吡啶基，任选取代的吲哚基，-NR 7 R 8; 或-NH-N = CH-R 9; 并且取代基R 5至R 9具有在说明书中指出的含义，特别是乙二胺。药物组合物可用于例如治疗多重耐药性结核病。

6. 发明申请

WO2004077064A1 DETECTION AND IDENTIFICATION OF ANTI-INFECTIVE COMPOUNDS INVOLVING DEPRESSION 审中-公开
标题翻译：涉及感染的抗感染化合物的检测和鉴定
公开(公告)号：WO2004077064A1
公开(公告)日：2004-09-10
申请号：PCT/EP2004/001822
申请日：2004-02-25
申请人： FUSSENEGGER, Martin , WEBER, Wilfried
发明人： FUSSENEGGER, Martin , WEBER, Wilfried
IPC分类号： G01N33/94
CPC分类号： G01N33/9446 , G01N2500/02 , G01N2500/20
摘要： The present invention is directed to a method for the in vitro detection, quantification and discovery of anti-infective compounds by measuring the change in interaction of a repressor protein with a polynucleotide-based protein binding partner (e.g. an operon) in response to the addition of known or potential anti-infective compounds in a cell-free environment. In vitro assays useful in such a method, e.g. in vitro assays wherein the protein binding partner is immobilized on a solid support or in vitro assays wherein the interaction of the repressor protein with its protein binding partner is measured in solution, and kits for such cell-free in vitro assays are described. The invention is also directed to novel anti-infective compounds detected by using the method of the invention, and to methods of identifying new proteins and protein binding partners useful in said method.
摘要翻译：本发明涉及一种通过测量阻抑蛋白与基于多核苷酸的蛋白质结合配偶体（例如操纵子）相互作用的变化的体外检测，定量和发现抗感染化合物的方法已知或潜在的抗感染化合物在无细胞环境中。用于这种方法的体外测定，例如其中蛋白质结合配偶体被固定在固体支持物上或体外测定中的体外测定，其中在溶液中测量阻抑蛋白与其蛋白质结合配偶体的相互作用，并描述了用于这种无细胞体外测定的试剂盒。本发明还涉及通过使用本发明的方法检测的新的抗感染化合物，以及用于鉴定在所述方法中有用的新蛋白质和蛋白质结合配偶体的方法。

7. 发明申请

WO2010149761A1 COMPOSITION FOR TREATMENT OF TUBERCULOSIS 审中-公开
标题翻译：用于治疗结肠癌的组合物
公开(公告)号：WO2010149761A1
公开(公告)日：2010-12-29
申请号：PCT/EP2010/059044
申请日：2010-06-25
申请人： BIOVERSYS GMBH , SCHOENMAKERS, Ronald , WEBER, Wilfried , GITZINGER, Marc , FUSSENEGGER, Martin , TIGGES, Marcel , SCHNEIDER, Peter
发明人： SCHOENMAKERS, Ronald , WEBER, Wilfried , GITZINGER, Marc , FUSSENEGGER, Martin , TIGGES, Marcel , SCHNEIDER, Peter
IPC分类号： A61K31/341 , A61K31/40 , A61K31/167 , A61K31/4015 , A61K31/4433 , A61K31/4439 , A61K31/495 , A61K31/496 , A61K31/5375 , A61K31/5377 , A61P31/06 , A61K31/17 , A61K31/397 , A61K31/44 , A61K31/443
CPC分类号： A61K31/4015 , A61K31/167 , A61K31/17 , A61K31/341 , A61K31/397 , A61K31/40 , A61K31/44 , A61K31/443 , A61K31/4439 , A61K31/495 , A61K31/496 , A61K31/5375 , A61K31/5377 , A61K31/7008 , A61K45/06 , C07D205/04 , C07D207/08 , C07D207/12 , C07D213/38 , C07D213/74 , C07D241/04 , C07D265/30 , C07D295/185 , C07D307/32 , C07D401/06 , C07D413/02 , C07D413/04 , C07D413/06 , A61K2300/00
摘要： The invention relates to a pharmaceutical composition comprising a compound of formula (1) wherein R 1 is optionally substituted phenyl, optionally substituted pyridyl or optionally substituted indolyl; R 2 is (CH 2 ) n wherein n is 0,1,2,3 or 4; R 3 is (CH 2 ) m R 3A wherein m is 0,1,2,3 or 4, and R 3A is methyl, isopropyl, tert-butyl, OCH 3 , OH, optionally substituted phenoxy, C≡CH, C≡N, optionally substituted phenyl, furanyl or thienyl; A is a ring containing X 1 with the meaning O, S, NH, N(CH 3 ) or CH 2 ; and X 2 is O, S or NH; and a compound of formula (2) wherein R 4 is optionally substituted phenyl, optionally substituted pyridyl, optionally substituted indolyl, -NR 7 R 8 ; or -NH-N=CH-R 9 ; and substituents R 5 to R 9 have the meanings indicated in the description, in particular ethionamide. The pharmaceutical composition is useful, e.g., in the treatment of multidrug-resistant tuberculosis.
摘要翻译：本发明涉及包含式（1）化合物的药物组合物，其中R 1是任选取代的苯基，任选取代的吡啶基或任选取代的吲哚基; R2是（CH2）n，其中n是0,1,2,3或4; R3是（CH2）m R3A，其中m是0,1,2,3或4，R3A是甲基，异丙基，叔丁基，OCH3，OH，任选取代的苯氧基，C = CH，C = N，任选取代的苯基，呋喃基或噻吩基; A是含有O，S，NH，N（CH 3）或CH 2的X 1的环; X2是O，S或NH; 和式（2）的化合物，其中R 4是任选取代的苯基，任选取代的吡啶基，任选取代的吲哚基，-NR 7 R 8; 或-NH-N = CH-R 9; 并且取代基R 5至R 9具有在说明书中指出的含义，特别是乙二胺。药物组合物可用于例如治疗多重耐药性结核病。

8. 发明申请

WO2010115583A1 CONTROLLING TRANSGENE EXPRESSION ACROSS THE SKIN 审中-公开
标题翻译：控制皮肤的转运表达
公开(公告)号：WO2010115583A1
公开(公告)日：2010-10-14
申请号：PCT/EP2010/002103
申请日：2010-04-01
申请人： ETH ZURICH , FUSSENEGGER, Martin , GITZINGER, Marc
发明人： FUSSENEGGER, Martin , GITZINGER, Marc
IPC分类号： C12N15/09
CPC分类号： C12N15/8509 , A61K9/0014 , A61K47/10 , C12N2820/55 , C12N2830/002 , C12N2830/005
摘要： The invention relates to the use of a skin permeating compound such as phloretin for controlling transgene expression under control of the Pseudomonas putida DOT-T1E- derived bacterial repressor TtgR, to a vector comprising the genetic code for the repressor TtgR fused to a transactivation or a transrepressor domain, to a vector comprising a TtgR- specific operator sequence (O TtgR ), a promoter and a polynucleotide coding for an endogenous or exogenous protein, and to a mammalian cell transiently or constitutively transfected with the mentioned vectors, and to mammals comprising such cells in nano- or microcontainers.
摘要翻译：本发明涉及皮肤渗透化合物如延胡索素用于在恶臭假单胞菌DOT-T1E衍生的细菌阻遏物TtgR的控制下控制转基因表达的用途，所述载体包含与转录激活融合的阻遏物TtgR的遗传密码反义阻抑物结构域，包含TtgR特异性操纵子序列（OTtgR），启动子和编码内源或外源蛋白的多核苷酸的载体，以及用所述载体瞬时或组成型转染的哺乳动物细胞，以及包含该细胞的哺乳动物在纳米或微型容器中。

9. 发明申请

WO2010004018A2 DEGRADABLE MICROCAPSULES 审中-公开
标题翻译：可降解微生物
公开(公告)号：WO2010004018A2
公开(公告)日：2010-01-14
申请号：PCT/EP2009/058792
申请日：2009-07-10
申请人： ETH ZURICH , SWISSGENETICS , KEMMER, Christian , FLURI, David , WITSCHI, Ulrich , WEBER, Wilfried , FUSSENEGGER, Martin
发明人： KEMMER, Christian , FLURI, David , WITSCHI, Ulrich , WEBER, Wilfried , FUSSENEGGER, Martin
IPC分类号： A61K9/50
CPC分类号： A61K35/52 , A61K9/5042 , A61K9/5068
摘要： The invention relates to microcapsules consisting of a polymer degradable by a polypeptide comprising a drug or other compound of interest and a genetically engineered cell expressing said polypeptide in response to a triggering compound, and to methods of directed release of the compound of interest. The preferred polymer is optionally modified cellulose sulfate / poly-diallyl-dimethyl-ammonium chloride. Such microcapsules are non-toxic, do not elicit an immunological response and have an extended half-life time in mammals. The expression system for cellulase is, for example, based on TET and doxycycline, or E.REX and erythromycin. In another example, expression of cellulase is triggered by luteinizing hormone, which can be used for artificial insemination with microcapsules carrying sperm.
摘要翻译：本发明涉及由可由可包含药物或目的的其它化合物的多肽降解的聚合物和响应于引发化合物表达所述多肽的遗传工程改造的细胞组成的微胶囊以及目的化合物的定向释放方法。优选的聚合物是任选改性的硫酸纤维素/聚二烯丙基二甲基氯化铵。这样的微胶囊是无毒的，不引起免疫应答并且在哺乳动物中具有延长的半衰期。纤维素酶的表达系统例如是基于TET和多西环素，或E.REX和红霉素。在另一个实例中，纤维素酶的表达由黄体生成激素引发，其可用于携带精子的微胶囊的人工授精。

10. 发明申请

WO2003025184A1 ANTIBIOTIC-BASED GENE REGULATION SYSTEM 审中-公开
标题翻译：抗生素基因调控系统
公开(公告)号：WO2003025184A1
公开(公告)日：2003-03-27
申请号：PCT/IB2002/003671
申请日：2002-09-06
申请人： FUSSENEGGER, Martin , WEBER, Wilfried
发明人： FUSSENEGGER, Martin , WEBER, Wilfried
IPC分类号： C12N15/63
CPC分类号： C12N15/635 , A01K2217/05 , C12N15/8238 , C12N2799/021
摘要： The invention relates to a novel system for gene regulation in eukaryotic cells, and methods of using the same for protein production, tissue engineering and gene therapy. In particular, the invention provides a new system for antibiotic-regulated gene expression in eukaryotic cells based on sequences from Enterobacteriaceae antibiotic resistance promoters, polypeptides that bind to the same in an antibiotic responsive manner, and nucleotides encoding such polypeptides. Further, the invention provides novel and sensitive methods of screening for candidate antibiotics.
摘要翻译：本发明涉及一种用于真核细胞中基因调控的新系统，以及用于其中的蛋白质生产，组织工程和基因治疗的方法。特别地，本发明基于肠杆菌科抗生素抗性启动子，以抗生素反应性方式与其结合的多肽和编码这些多肽的核苷酸的序列，提供了真核细胞中抗生素调节基因表达的新系统。此外，本发明提供了筛选候选抗生素的新型和敏感的方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式